Source - SMW
Silence Therapeutics has sold a further part of its holding in Arrowhead Pharmaceuticals.

Since an announcement on 11 December 2017, Silence has sold a further 2,317,693 shares for an average selling price of $3.60. The Company still holds 472,509 common shares which represents 0.63% of Arrowhead. 

The company will use the proceeds from the sale of the shares to fund working capital requirements.